AIR DNAse appears to treat sputim viscosity (mucus, pus, etc...) therefore imho Corbus's candidate is separate from PLX's.

I'm going to Watch the volume for Freddie/Fannie on Tuesday and Wednesday for any unusual action as well as to see if the sp is drawn down or not those 2 days for big money to gobble up cheapies. This info will dictate when and how much I buy. Thursday imho will be an awesome day for shareholders. I currently have 0 shares in both. Good luck .....

Thanks for the tip. I like what I see so far. It's also a plus to have DD on board as a mod. I will definitely join the board in the next 2 weeks. I have to first watch Mnuchin on Thursday get grilled and see what he says about the GSE's. $FMCC $FNMA. I will be a buyer on Wed. for $FMCC and than on to $ADXS.

On my watch list. Thanks Vid for being you. I was in the camp wanting to see 2019 a year after profitability, but for now it's a great deal. I'm gonna just enjoy this new sense of mellow, relaxed state of mind and just wait for market correction before diving on in. See ya !!!!!!!!

HaHa !!!! Nice to be a part of this forum. Hope to see some of you guys in future forums ..... Happy Birthday to me (This Friday the 13th)

Change 120 to 750 and to me that would be more realistic. Just my humble opinion of course. The tough part would be to stay financially stable and have increased revenue over the next 2 years. Still waiting on pricing agreement from Japan. Not sure why that hasn't been agreed on yet. I still believe we get sold this year but if not I'm ready to hold on longer but with a tight stop once we get near $20. Good luck to you and every one else. Happy New Years.

Curious if Ariad did want to do this alone and instead of offering shares via an add on or secondary or whatever you want to call it would it be better if Ariad and a broker came to an agreement to sell a X amount of shares via the ATM (at the market rate) over a period of time. This is above my pay grade and am curious what other minds may think about this possible scenario. Even if it's done to payoff there debt ..... ?????

10:00 a.m. E.S.T.

$14 calls @ a price of .40 per contract it looks like. His/Her bet on stock price is $14.40 or more by expiration.

*** Edit *** You beat me to it B ....

Did not know 45 days after. Learn something new every day. Thanks.

Agreed. I didn't see any float numbers there, so I go by what's on this site unless I feel it's out of date the info.

The detailed quote for Ariad on IHUB. It isn't accurate on all tickers but with Ariad the short numbers are accurate so I have to believe the float is. The institutional numbers have not been updated yet. Click here: http://ih.advfn.com/exchanges/NASDAQ/ARIA/stock-price

Just a small correction. The float currently is 157.75 million.

The Letter:

http://www.sanders.senate.gov/download/letter-to-ariad?inline=file

Green after all this tells you something sinister is going on here.

In the next month expect a response from the FDA regarding Ariad's request for priority review on Brig. On the FDA website it says a request for priority review will be acted on within 60 days. Not sure if that means 60 business days or not.

Only 500+ shares total. Be careful ...

Wow. All aboard !!!! Next stop $8.00. Woot Woot !!!!

Shorties are very stubborn. A couple of cases in point Chanos shorted Valeant in the 100's and almost choked when Valeant hit $290. Turned out to be the right move for him and he still didn't cover, even after going down into the $20's. Another example is with the 30M shares shorted on $EXAS when it was brought down to the upper $4's to go back to $19. Though decreased in short positions , still around 22M. Personally I hope they hang around till the end of this story called $ARIA !!!!!

As far as their IPO i know of no such thing. Corbus filed papers to get on the exchange without any public offering. Smart move imho considering the small outstanding share number and float.

I agree.

It Appears they may have reduced there exposure down from 15M shares if i'm reading this correctly. I know as of 6/30 Putnam reduced there exposure by 17% down to 15M. I wouldn't good or bad in either case because some entity bought these shares in the 10's. We should be seeing those filings shortly imho.

Day traders have been killing it since I've been here Nov. '13. Imagine being the lucky fellow/s who bought in the 4's and sold in the 9's-10's three times since Oct'13 and having the turn of fortune as far as the company's perception goes on Wall Street at this juncture. But I for one feel pretty damn good about this stock now and it's only going to get better.

Kind of a generic obvious answer but imho exceeding earnings and/or revenue quarter after quarter will do the pps more than anything. Obviously management's execution of "the plan" needs to go flawlessly for that to happen, Iclusig sales worldwide and bringing Brig to market asap. Ariad cannot afford to trip over their toes while executing their plan. Maybe the shorts are hoping that is going to happen. I would hate to be betting on that considering the growth in Europe for Iclusig even though it adds up to a royalty share, and the way management has so far conducted their business.

Under New Structure, ARIAD Growth Opportunities May Be Undervalued


http://seekingalpha.com/article/4001629-new-structure-ariad-growth-opportunities-may-undervalued?auth_param=lfr8v:1brp9d7:584fe4cd0f386a6ce2377ce5345b7003&dr=1&uprof=45&utoken=789cb41709411b3f7b01bfc1ff5abd2c

I am intrigued by these particular numbers from NASDAQ:
New Positions 29 9,929,158
Sold Out Positions 20 922,817

Shorts are sweating but I think they hang in there until the end. Just my humble opinion.

From Fidelity: ValuEngine upgrades ARIAD PHARMACEUTICALS INC from HOLD to BUY. BY Investars Analyst Actions - public
— 7:17 AM ET 08/12/2016 On August 11, 2016 ValuEngine upgraded ARIAD PHARMACEUTICALS INC ( ARIA Loading... Loading...
) from HOLD to BUY.

On Fidelity account I got this morning under Ariad news:


Thomson Reuters/Verus upgrades ARIAD PHARMACEUTICALS INC from HOLD to BUY.
BY Investars Analyst Actions - public
— 10:19 AM ET 08/08/2016

On August 8, 2016 Thomson Reuters/Verus upgraded ARIAD PHARMACEUTICALS INC ( ARIA
Loading... Loading...
) from HOLD to BUY.

The float is now under 158M shares. If memory serves me correctly this amounts to 20% less from a year ago. Shorts are indeed in trouble if this trend is continuing and if it is part of the master plan to bring share holder value. Buy Buy Buy !!!!!!

Looking forward in high anticipation of a major break out off a double top when $10.07 is passed. We will know by than if the shorts intend to hang around. It can be "kaboom" time or we will simply retrace back before the next leg up. Maybe we form a handle here, but Ariad hasn't been good with holding handles in recent history.

I was just thinking the same thing. There was a 500,000 share block processed @ 14:03. Not sure if it was a buy or sell though.

Vid,

From the Call ...

• ARIAD has submitted the four-year PACE data to the FDA and other health authorities as a label supplement, with an FDA action date in the fourth quarter of this year.

EVA Dimensions, LLC upgrades ARIAD PHARMACEUTICALS INC from SELL to UNDERWEIGHT.
BY Investars Analyst Actions - public
— 8:07 AM ET 07/29/2016

On July 29, 2016 EVA Dimensions, LLC upgraded ARIAD PHARMACEUTICALS INC ( ARIA
Loading... Loading...
) from SELL to UNDERWEIGHT.

6 to 10 months. 10 months for standard review, 6 months for drugs that offer major advances in treatment, or provide a treatment where none exist

Amen to that. Couldn't have said it better. If people can't handle the volatility they need to not invest in biotech, never mind Ariad alone.

I will agree with this comment, even 2 years from now you can probably say this too. However, I am curious what valuation you place in for an intrinsic value for the company including all aspects of the business (tangible and intangible assets). My opinion currently resides at about $13 which makes this a screaming buy. As time passes and the strategy for the company unfolds financially speaking, my number will go up or down depending on what management does to resolve financing beyond 2017.

Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure).

Info from this link: https://clinicaltrials.gov/ct2/show/study/NCT02467270?term=ponatinib&rank=5&show_locs=Y#locn

If you go by Jefferies & Co. analyst Eun Yang, Ph.D. and if she is correct FY2018 earnings at $0.27 EPS and FY2019 earnings at $0.83 EPS you can assume a fair market value sp of 6.75 for 2018 and a sp of 20.75 for 2019. I am not sure if she is only basing the EPS based on Iclusig alone or not.

Seemed like a good place to start. A 20 multiple is what I am hoping for minimum. But we won't know until Ariad is profitable.

You're right. I forgot about Uncle Sam.